In Indonesia, as in many other nations, cancer stands as a major public health concern, with the most prevalent types including breast, cervical, lung, colorectal, and liver cancer. The country encounters distinct obstacles in cancer care, such as limited access to programs for early detection, a deficit in healthcare facilities and oncology specialists, and the prohibitive costs associated with treatment. Furthermore, a general lack of awareness regarding cancer prevention and the importance of early detection contributes to diagnoses at advanced stages and diminished survival rates. Consequently, the advancement of oncology in Indonesia is geared towards enhancing early detection and screening initiatives, raising public awareness about cancer, and improving the healthcare system along with making treatments more accessible and affordable. Additionally, there is an increasing inclination towards combining traditional and modern cancer treatment methods to offer comprehensive care to patients.

The field of clinico-genomic research holds considerable promise for oncology in Indonesia by pinpointing genetic and molecular markers unique to the Indonesian populace that influence cancer susceptibility, progression, and response to treatment. Our studies aim to facilitate personalized treatment approaches, which could significantly enhance treatment efficacy and potentially lower death rates. Moreover, by elucidating the genetic characteristics of prevalent cancers in Indonesia, such as those of the breast, lung, and cervix, we can develop focused strategies for screening and prevention, ultimately leading to improved health outcomes.